A Multicenter Phase 2 Study of Ibrutinib in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) With 17p Deletion

Completed · Phase 2

Conditions studied: Chronic Lymphocytic Leukemia With 17p Deletion, Small Lymphocytic Lymphoma With 17p Deletion

In brief

An Open-label, Single arm, Multicenter Phase 2 Study of the Bruton's Tyrosine Kinase Inhibitor ibrutinib in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma with 17p Deletion

Key facts

Study ID

NCT01744691

Run by

Pharmacyclics LLC.

People needed

145

Starts

2013-01-01

Expected to finish

2016-04-01

Last updated by the study team

2017-02-27

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Study site — Duarte, California, United States
• Study site — Greenbrae, California, United States
• Study site — La Jolla, California, United States
• Study site — Stanford, California, United States
• Study site — Tampa, Florida, United States
• Study site — Chicago, Illinois, United States
• Study site — Boston, Massachusetts, United States
• Study site — Ann Arbor, Michigan, United States
• Study site — Rochester, Minnesota, United States
• Study site — St Louis, Missouri, United States
• Study site — Hackensack, New Jersey, United States
• Study site — New Hyde Park, New York, United States
• Study site — New York, New York, United States
• Study site — Goldsboro, North Carolina, United States
• Study site — Columbus, Ohio, United States
• Study site — Toldedo, Ohio, United States
• Study site — Houston, Texas, United States
• Study site — Adelaide, Australia
• Study site — Coburg, Australia
• Study site — East Melbourne, Australia
• Study site — Fremantle, Australia
• Study site — Antwerp, Belgium
• Study site — Bruges, Belgium
• Study site — Brussels, Belgium
• Study site — Phoenix, Arizona, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.